Metrion Biosciences, the specialist ion channel CRO and drug discovery company, has promoted Andrew Southan to Chief Operating Officer and James Beaumont as Head of Business Development.
“Andy Southan has made a major contribution to Metrion since joining the business last year as Head of Commercial Operations. Andy’s promotion to COO reflects Metrion’s rapid growth and the confidence we have in his management capabilities,” said Keith McCullagh, Chair of Metrion Biosciences.
James Beaumont
Beaumont brings more than 20 years’ sales, business development and marketing experience within the pharmaceutical and biotechnology sector, besides an extensive network of senior-level contacts across Europe, North America and New Zealand.
He initially trained as a chemist and obtained both his honours degree and MSc from the University of Sheffield. Beaumont has successfully managed multimillion sales budgets within the CRO life sciences sector.
Andrew Southan
Southan joined Metrion in October 2016 and has more than 25 years’ experience within the life sciences sector, including 14 years managing CRO services.
“James brings a wealth of experience from senior roles in sales and business development at a variety of life science CRO companies, including Evotec, Aptuit and New Zealand Pharmaceuticals,” said McCullagh.
James Beaumont commented: “The field of ion channel drug discovery is in its infancy and there is a major opportunity to bring the company’s technical leadership in this field to the international drug discovery and safety testing markets.”
